APETx2是一种来自Anthopleura elegantissima的肽毒素,是选择性、可逆的酸敏感离子通道3(ASIC3)抑制剂。
Cas No.:713544-47-9
Sample solution is provided at 25 µL, 10mM.
APETx2 is a peptide toxin derived from Anthopleura elegantissimaand serves as a selective, reversible inhibitor of the acid-sensing ion channel 3 (ASIC3)[1-2]. By inhibiting the activity of the ASIC3 channel, APETx2 blocks acid-induced pain signaling. APETx2 can be used in research related to inflammatory pain, post-infectious irritable bowel syndrome, and gastric mucosal injury[3-4].
In vitro, rat articular chondrocytes were pretreated with APETx2 (3µM) and PcTx1 (100ng/ml) for 1 hour, followed by incubation under acidic conditions (pH=6.0) for 3 hours. APETx2 significantly alleviated acidosis-induced cytotoxicity and apoptosis, exerting a chondroprotective effect by reducing intracellular Ca²⁺ levels and inhibiting the phosphorylation of the p38/ERK1/2 MAPK signaling pathway[5]. Under magnesium-free medium conditions (used to induce epileptiform discharge), primary hippocampal neurons were incubated with APETx2 (63nM) for 1 hour. APETx2 significantly increased the frequency of burst discharges induced by the magnesium-free medium[6].
In vivo, APETx2 (20pmol per mouse) was injected into the Zusanli acupoint (ST36) of a fibromyalgia mouse model. By antagonizing ASIC3, APETx2 significantly reduced mechanical hyperalgesia on day 14 post-induction and decreased the overexpression of pain-related channel proteins ASIC3, Nav1.7, and Nav1.8 in the dorsal root ganglia, spinal cord, and thalamus[7]. In a rat model of osteoarthritis, daily continuous intra-articular injections of APETx2 (2.5µg/kg) for 7 days, APETx2 significantly inhibited weight-bearing asymmetry and secondary mechanical hyperalgesia in the knee joint. APETx2 also effectively prevented articular cartilage damage by reducing chondrocyte loss and matrix destruction[8].
References:
[1] Yuan L, Xiao H, Li H, et al. APETx2 regulates intestinal motility and visceral sensitivity in post-infectious irritable bowel syndrome mice through 5-HT signalling pathway. J Pharm Pharmacol. 2023 Apr 17;75(5):712-717.
[2] Li J, Wei Y, Wang Y, et al. Metabolomics study of APETx2 post-conditioning on myocardial ischemia-reperfusion injury. Front Pharmacol. 2024 Dec 6;15:1470142.
[3] Diochot S, Baron A, Rash LD, et al. A new sea anemone peptide, APETx2, inhibits ASIC3, a major acid-sensitive channel in sensory neurons. EMBO J. 2004 Apr 7;23(7):1516-25.
[4] Chagot B, Escoubas P, Diochot S, et al. Solution structure of APETx2, a specific peptide inhibitor of ASIC3 proton-gated channels. Protein Sci. 2005 Aug;14(8):2003-10.
[5] Zhou RP, Ni WL, Dai BB, et al. ASIC2a overexpression enhances the protective effect of PcTx1 and APETx2 against acidosis-induced articular chondrocyte apoptosis and cytotoxicity. Gene. 2018 Feb 5;642:230-240.
[6] Cao Q, Xiao ZM, Wang X, et al. Inhibition of Acid Sensing Ion Channel 3 Aggravates Seizures by Regulating NMDAR Function. Neurochem Res. 2018 Jun;43(6):1227-1241.
[7] Yen LT, Hsieh CL, Hsu HC, et al. Preventing the induction of acid saline-induced fibromyalgia pain in mice by electroacupuncture or APETx2 injection. Acupunct Med. 2020 Jun;38(3):188-193.
[8] Izumi M, Ikeuchi M, Ji Q, et al. Local ASIC3 modulates pain and disease progression in a rat model of osteoarthritis. J Biomed Sci. 2012 Aug 21;19(1):77.
APETx2是一种来自Anthopleura elegantissima的肽毒素,是选择性、可逆的酸敏感离子通道3(ASIC3)抑制剂[1-2]。APETx2通过抑制ASIC3通道的活性,以阻断酸诱导的疼痛信号传导。APETx2可用于炎症性疼痛、感染后肠易激综合征和胃黏膜损伤的相关研究[3-4]。
在体外,APETx2(3µM)及PcTx1(100ng/ml)预处理大鼠关节软骨细胞1小时,随后在酸性(pH=6.0)条件下培养3小时。APETx2能显著减轻酸化诱导的细胞毒性与凋亡,并通过降低细胞内Ca²⁺水平及抑制p38/ERK1/2/MAPK信号通路磷酸化,发挥软骨保护作用[5]。在不含Mg²⁺的培养基(用于诱导癫痫样放电)的条件下,APETx2(63nM孵育)海马神经元细胞1小时,APETx2显著增强了由无镁培养基诱导的爆发性放电频率[6]。
在体内,向纤维肌痛小鼠模型的足三里穴(ST36)注射APETx2(20pmol/只),APETx2通过拮抗酸性离子通道3(ASIC3),显著减轻了诱导后第14天的机械性痛觉过敏,并降低了背根神经节、脊髓和丘脑中与疼痛相关的ASIC3、Nav1.7和Nav1.8通道蛋白的过表达[7]。在骨关节炎模型大鼠膝关节中,每日连续注射APETx2(2.5μg/kg),持续7天,APETx2显著抑制了膝关节的负重分布不对称性以及继发性机械性痛觉过敏。APETx2还通过减少关节软骨细胞丢失和基质破坏,有效防止了关节软骨损伤[8]。
| Cell experiment [1]: | |
Cell lines | Articular chondrocytes |
Preparation Method | Articular chondrocytes were cultured in DMEM supplemented with 10% fetal bovine serum (FBS) at 37°C, 5% CO₂. Cells were pretreated with ASIC3-specific blocker APETx2 (3μM) for 1 hour, and exposure to pH 6.0 solution for 3 hours. |
Reaction Conditions | 3μM; 1-hour pretreatment. |
Applications | Pretreatment with APETx2, in combination with the ASIC1a-specific blocker PcTx1, significantly attenuated acidosis (pH=6.0)-induced chondrocyte cytotoxicity and apoptosis. This protective effect was characterized by increased cell viability, reduced LDH release, decreased intracellular Ca²⁺ concentration ([Ca²⁺]i) elevation, reduced apoptotic rate, and inhibition of the p38 and ERK1/2 MAPK signaling pathways. Additionally, the combination treatment (PcTx1 and APETx2) reversed the acid-induced decrease in type II collagen levels. |
| Animal experiment [2]: | |
Animal models | Male Sprague-Dawley rats (with MIA-induced osteoarthritis model) |
Preparation Method | A single dose of monosodium iodoacetate (MIA, 3mg dissolved in 50μl saline) was injected into the left knee joint to induce osteoarthritis. Rats were treated with intra-articular injections of the selective ASIC3 blocker APETx2 (2.5μg/kg) daily, either during the early phase (Days 1-7 after MIA) or the late phase (Days 7-13 after MIA). Pain-related behaviors (weight distribution asymmetry and mechanical hyperalgesia) were assessed at specified time points, and histological evaluation of knee joints was performed at Day 14. |
Dosage form | 2.5μg/kg; intra-articular injection; Daily continuous injection. |
Applications | Continuous administration of APETx2 inhibited the upregulation of ASIC3 in knee joint afferent neurons. APETx2 significantly reduced mechanical hyperalgesia (secondary hyperalgesia) in both early- and late-phase treatment groups. APETx2 also significantly inhibited weight distribution asymmetry in the early-phase group at Day 3. Furthermore, early administration of APETx2 (Days 1-7) prevented cartilage damage and reduced the severity of osteoarthritis, as evidenced by improved histological scores (modified Mankin score). |
References: | |
| Cas No. | 713544-47-9 | SDF | |
| Canonical SMILES | CCC(C(/N=C(O)/C/N=C(O)/C(/N=C(O)/C(/N=C(O)/C(/N=C(O)/C/N=C(O)\C1CSSCC(N=C(O)C(N=C(O)CN=C(O)C(N=C(O)C(N=C(O)CN=C(O)C(N=C(O)C(N=C(O)C(N=C(O)C2CCCN23)C(O)C)CC(O)=O)CCCNC(N)=N)CC4=CC=C(O)C=C4)C(O)C)CO)/C(O)=N/C(/C(O)=N/C(/C(O)=N/C(/C(O)=N/C(/C(O)=N/C/C(O)=N/C | ||
| 分子式 | C196H280N54O61S6 | 分子量 | 4561.06 |
| 溶解度 | Soluble to 5 mg/ml in Water | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
| 1 mM | 219.2 μL | 1.0962 mL | 2.1925 mL |
| 5 mM | 43.8 μL | 219.2 μL | 438.5 μL |
| 10 mM | 21.9 μL | 109.6 μL | 219.2 μL |
| 第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
| 给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
| 第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
















